DALLAS, July 27, 2020 -- A genetic difference in one gene common in people of East Asian descent may make them more susceptible to adverse responses to e-cigarettes, according to preliminary research to be presented July 27-30, 2020, at the American Heart Association's virtual Basic Cardiovascular Sciences 2020 Scientific Sessions. The meeting is a premier global exchange of the latest advances in basic cardiovascular science including research in fields like microRNAs, cardiac gene and cell therapy, and cardiac development.
"This study highlights the importance of understanding the interplay of genetics with e-cigarette aerosol exposure, as some people may be more susceptible to oxidative damage from smoking e-cigarettes," said Xuan Yu, M.D., Ph.D., lead author of the study and a postdoctoral research fellow in the Gross Lab at Stanford University in Stanford, California.
The genetic variant, or difference found in a single gene, causes a deficiency of the enzyme aldehyde dehydrogenase 2 (ALDH2), which makes it difficult to metabolize aldehydes. The variant is estimated to occur in about 540 million people worldwide, about 8% of the world's population, mainly those of descent from East Asian countries (China, Japan, North Korea, South Korea or Taiwan). Previously, the best-known symptoms of ALDH2-deficiency have been increased heart rate and facial flushing when alcohol is consumed. This is because these individuals have difficulty metabolizing acetaldehyde - a toxic breakdown product of alcohol.
"Having this genetic variant can increase your risk of cardiovascular disease or cancer, particularly combined with lifestyle choices such as consuming alcohol or smoking tobacco cigarettes," said Eric R. Gross M.D., Ph.D., the senior author of the study, assistant professor of anesthesiology, perioperative and pain medicine, and principal investigator of the Gross Lab at Stanford University. "One in three people of East Asian descent have this gene. While commercial tests are available to detect ALDH2, most adults have a good idea if they have this genetic variant after alcohol consumption."
While e-cigarette users often believe that electronic nicotine delivery devices are safer than smoking, and they do have some different chemicals than conventional tobacco cigarettes, e-cigarettes contain or produce several potential toxic aldehydes, including acetaldehyde, formaldehyde and acrolein. In this study, researchers tested whether mice that are genetically engineered to have ALDH2-deficiency react differently to e-cigarette exposure than mice without the deficiency. During 7-minute sessions, four times per day for 10 days, mice were exposed to either 14 puffs of room air or to 14 puffs of e-cigarette aerosol.
- while mice normally have a heart rate 9 times higher than humans, after exposure to the e-cigarette aerosols, the heart rate of the ALDH2-deficient mice jumped 24% (to 775 beats per minute) versus 11% in mice without the enzyme deficiency (to 679 beats per minute); and
after 10 days of exposure, chemical analysis of heart tissue showed that the ALDH2-deficient mice exposed to e-cigarettes had between 20% and 100% more signs of oxidative stress within heart cells compared to the ALDH2-deficient mice exposed only to air.
"Oxidative stress is controlled by the balance in your body between harmful chemicals such as reactive aldehydes, and the defenses your body uses to neutralize these chemicals," said Yu. "Elevated oxidative stress raises the risks of atherosclerosis and a heart attack."
The researchers were surprised that exposure to e-cigarette aerosols also caused slight increases in heart rate and oxidative stress levels in mice without ALDH2-deficiency.
"When parents discuss e-cigarettes with their children, the messages should be that nicotine is addictive and e-cigarettes contain toxic chemicals. We currently need more extensive research to fully understand the potential harmful effects of e-cigarette use in addition to the underlying mechanism of e-cigarette or vaping-associated lung injury," Gross said.
"This study is important and confirms that additional research in humans is needed to fully understand the impact of e-cigarettes" said Rose Marie Robertson, M.D., FAHA, the American Heart Association's deputy chief science and medical officer and co-director of the AHA Tobacco Center for Regulatory Science who was not involved in the study. "If e-cigarettes do impact people with ALDH2 deficiency differently, then the public needs to be warned about these potentially serious health risks."
Co-authors are Xiaocong Zeng, M.D., Ph.D.; Ri Chen, B.S.; Pritam Sinharoy, Ph.D.; and Eric R. Gross, M.D., Ph.D. Author disclosures are in the abstract.
The Tobacco-Related Disease Research Program of California and the National Heart, Lung, and Blood Institute of the National Institutes of Health funded the study.
Available multimedia is on the right column of the release link - https:/
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https:/
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.